Search: WFRF:(Nordenskjöld Bo 1940 ) >
Amplification of HS...
Amplification of HSD17B1 and ERBB2 in primary breast cancer
-
- Gunnarsson, Cecilia, 1970- (author)
- Linköpings universitet,Onkologi,Hälsouniversitetet
-
- Ahnström, Marie, 1976- (author)
- Linköpings universitet,Onkologi,Hälsouniversitetet
-
- Kirschner, Kristina (author)
- Linköpings universitet,Kirurgi,Hälsouniversitetet
-
show more...
-
- Olsson, Birgit, 1946- (author)
- Department of Oncology, Huddinge University Hospital, Stockholm, Sweden
-
- Nordenskjöld, Bo, 1940- (author)
- Linköpings universitet,Onkologi,Hälsouniversitetet
-
- Rutqvist, Lars Erik (author)
- Department of Oncology, Huddinge University Hospital, Stockholm, Sweden
-
- Skoog, Lambert (author)
- Karolinska Institutet
-
- Stål, Olle, 1952- (author)
- Linköpings universitet,Onkologi,Hälsouniversitetet
-
show less...
-
(creator_code:org_t)
- 2003-01-14
- 2003
- English.
-
In: Oncogene. - : Springer Science and Business Media LLC. - 0950-9232 .- 1476-5594. ; 22:1, s. 34-40
- Related links:
-
https://www.nature.c...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Estrogens play a crucial role in the development of breast cancer. Estradiol can be produced in the breast tissue in situ, and one of the enzymes involved in this process is 17β-hydroxysteriod dehydrogenase (17β-HSD) type 1 that catalyzes the interconversion of estrone (E1) to the biologically more potent estradiol (E2). The gene coding for 17β-HSD type 1 (HSD17B1) is located at 17q12-21, close to the more studied ERBB2 and BRCA1. The aim of this study was to investigate if HSD17B1 shows an altered gene copy number in breast cancer. We used real-time PCR and examined 221 postmenopausal breast tumors for amplification of HSD17B1 and ERBB2. In all, 32 tumors (14.5%) showed amplification of HSD17B1 and 21% were amplified for ERBB2. Amplification of the two genes was correlated (P = 0.00078) and in 14 tumors (44%) with amplification of HSD17B1, ERBB2 was co amplified. The patients with amplification in at least one of the genes had a significantly worse outcome than patients without (P = 0.0059). For estrogen receptor (ER)-positive patients who received adjuvant tamoxifen, amplification of HSD17B1 was related to decreased breast cancer survival (P = 0.017), whereas amplification of ERRB2 was not. Amplification of HSD17B1 might be an indicator of adverse prognosis among ER-positive patients, and possibly a mechanism for decreased benefit from tamoxifen treatment.
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Oncogene
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Gunnarsson, Ceci ...
-
Ahnström, Marie, ...
-
Kirschner, Krist ...
-
Olsson, Birgit, ...
-
Nordenskjöld, Bo ...
-
Rutqvist, Lars E ...
-
show more...
-
Skoog, Lambert
-
Stål, Olle, 1952 ...
-
show less...
- Articles in the publication
-
Oncogene
- By the university
-
Linköping University
-
Karolinska Institutet